HemaSphere
(May 2023)
P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY
- M. Roussel,
- N. Texier,
- R. Germain,
- S. Sapra,
- P. Paka,
- N. Kerbouche,
- X. Colin,
- X. Leleu
Affiliations
- M. Roussel
- 1 Hématologie Clinique et Thérapie Cellulaire, CHU Dupuytren, Limoges, France
- N. Texier
- 2 Kappa Santé, Paris, France
- R. Germain
- 2 Kappa Santé, Paris, France
- S. Sapra
- 3 GSK, Upper Providence, PA, USA
- P. Paka
- 3 GSK, Upper Providence, PA, USA
- N. Kerbouche
- 4 GSK, Rueil-Malmaison, France
- X. Colin
- 4 GSK, Rueil-Malmaison, France
- X. Leleu
- 5 Département d’Hématologie, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France
- DOI
-
https://doi.org/10.1097/01.HS9.0000936260.48784.ae
- Journal volume & issue
-
Vol. 7,
no. S2
pp.
29
– 29
WeChat QR code